Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alcibiades Rodriguez

Clinical Neurophysiology New York, NY Medical Doctor

NPI 1831151281 CMS profile 128409

223 E 34Th St, New York, NY 10016

Open in the dashboard

General payments

$714,131

895 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,500 paid to institutions, not to them · program year 2020

Through program year 2025, Alcibiades Rodriguez of New York, NY is reported in the CMS Open Payments database as having received $714,131 across 895 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,500 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Clinical Neurophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $212,659 302
2024 General $177,637 250
2023 General $115,358 112
2022 General $56,051 57
2021 General $59,512 56
2020 General $35,293 42
2019 General $57,621 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alcibiades Rodriguez
  • Clinical Neurophysiology median
  • Middle half of Clinical Neurophysiology
  • National median

In program year 2025, general payments to Alcibiades Rodriguez were reported at $212,659. Among 259 Clinical Neurophysiology profiles paid that year, the median was $435 and the middle half received between $121 and $1,917.

Show as a table
Year Alcibiades Rodriguez Clinical Neurophysiology median Middle half National median
2019 $57,621 $306 $88–$1,636 $163
2020 $35,293 $299 $85–$1,847 $114
2021 $59,512 $325 $96–$2,308 $132
2022 $56,051 $395 $106–$1,957 $149
2023 $115,358 $388 $120–$1,718 $160
2024 $177,637 $471 $137–$1,931 $164
2025 $212,659 $435 $121–$1,917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Jazz Pharmaceuticals Inc. $321,090 329 payments
  2. Axsome Therapeutics, Inc. $143,845 110 payments
  3. Lilly USA, LLC $99,857 136 payments
  4. Harmony Biosciences LLC $80,646 170 payments
  5. Avadel CNS Pharmaceuticals, LLC $59,086 59 payments
  6. Eisai Inc. $4,918 2 payments
  7. Neurelis, Inc. $1,366 42 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $1,316 9 payments
  9. LivaNova USA, Inc. $800 1 payment
  10. UCB, Inc. $355 8 payments
  11. Other $853 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $370,784 175 payments
  2. Consulting Fee $123,304 49 payments
  3. Travel and Lodging $92,445 177 payments
  4. Honoraria $88,624 26 payments
  5. Food and Beverage $26,368 453 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $11,928 5 payments
  7. Education $679 10 payments
Products named General payments · program years 2019–2025
  1. XYWAV $212,950 198 payments
  2. Sunosi Neurology $143,845 110 payments
  3. ZEPBOUND $75,203 89 payments
  4. LUMRYZ $59,086 59 payments
  5. Wakix Neurological Disorders $43,967 54 payments
  6. SUNOSI Neurology $42,940 37 payments
  7. SUNOSI Pain $35,102 40 payments
  8. XYREM $27,874 40 payments
  9. WAKIX Narcoplepsy $24,577 74 payments
  10. WAKIX Sleep Medicine $7,074 15 payments
  11. Other $18,577 107 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

621

Median for Neurology: 833

Drug cost

$1,342,375

Median for Neurology: $202,670

Branded share of claims

25.3%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xywav Sodium,calcium,mag,pot Oxybate Brand 31 $619,141
Wakix Pitolisant Hcl Brand 20 $311,499
Lumryz Sodium Oxybate Brand 12 $239,796
Vimpat Lacosamide Brand 13 $65,927
Briviact Brivaracetam Brand 13 $39,500
Sunosi Solriamfetol Hcl Brand 30 $31,567
Lunesta Eszopiclone Brand 24 $20,665
Adderall Xr Dextroamphetamine/Amphetamine Brand 14 $7,357
Zaleplon Generic 102 $2,205
Doxepin Hcl Generic 38 $1,284

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$134,309

Medicare's payments for the services billed

Medicare patients

413

Average age 73

Services billed

664

197 women, 216 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 60%
Ischemic heart disease 40%
Diabetes 31%
Depression 29%
Atrial fibrillation 26%
Chronic kidney disease 25%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XYWAV
$60,494 31 —
Sunosi
$43,443 30 —
LUMRYZ
$39,500 12 —
WAKIX
$24,577 20 —
MOUNJARO
$5,868 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

895 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Neurophysiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record